Arcadia Biosciences, Inc. (RKDA) — SEC Filings
Arcadia Biosciences, Inc. (RKDA) — 33 SEC filings. Latest: 10-K/A (Apr 30, 2026). Includes 18 8-K, 5 10-Q, 3 10-K/A.
View Arcadia Biosciences, Inc. on SEC EDGAR
Overview
Arcadia Biosciences, Inc. (RKDA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: Arcadia Biosciences, Inc. filed an 8-K on December 29, 2025, reporting the termination of a material definitive agreement as of December 24, 2025. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company is incorporated in Delaware and headquartered in Dallas
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 2 bearish, 31 neutral. The dominant filing sentiment for Arcadia Biosciences, Inc. is neutral.
Filing Type Overview
Arcadia Biosciences, Inc. (RKDA) has filed 3 10-K/A, 18 8-K, 2 DEF 14A, 5 10-Q, 2 10-K, 1 8-K/A, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of RKDA's 29 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3,957,000 |
| Net Income | $856,000 |
| EPS | N/A |
| Debt-to-Equity | 0.58 |
| Cash Position | $1,120,000 |
| Operating Margin | -29.5% |
| Total Assets | $8,584,000 |
| Total Debt | $3,141,000 |
Key Executives
- Thomas J. Schaefer
- Albert D. Bolles
- Kevin Comcowich
- Elliott Roosevelt, Jr.
- David A. Roosevelt
- Michael McMillen
- Dr. Robert H. Smith
- Dr. David E. Nelson
- Dr. David J. E. Lowe
- Rajan S. Sajja
- Michael J. Ryan
Industry Context
Arcadia Biosciences operates in the agricultural technology and life sciences sector, focusing on developing and commercializing innovative seed traits and crop varieties. The industry is characterized by significant R&D investment, long product development cycles, and a complex regulatory environment. Key trends include the demand for sustainable agriculture, climate-resilient crops, and improved nutritional profiles.
Top Tags
Arcadia Biosciences (4) · SEC Filing (4) · corporate-governance (3) · sec-filing (3) · financial-reporting (3) · financials (3) · 10-Q (3) · disclosure (2) · Proxy Statement (2) · Corporate Governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-37383 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 81-0571538 | Company's tax identification number. |
| Date of 2025 Annual Meeting | December 19, 2025 | Virtual meeting at 1:00 p.m. Central Time |
| Record Date for Annual Meeting | November 4, 2025 | Stockholders of record as of this date may vote |
| Shares of Common Stock Outstanding | 1,373,120 | As of the Record Date, held by 36 holders of record |
| Number of Class I Directors to be Elected | 3 | Albert D. Bolles, Kevin Comcowich, and Thomas J. Schaefer |
| Fiscal Year End | December 31, 2025 | For which Deloitte & Touche LLP is appointed independent registered public accountant |
| Meeting Start Time | 1:00 p.m. Central Time | For the virtual 2025 Annual Meeting |
| Proxy Materials Availability Date | November 19, 2025 | Date proxy statement and form of proxy were first mailed |
| Quorum Requirement | 1/3 | One-third of aggregate voting power required to conduct business |
| Net income for Q3 2025 | $856,000 | Improved from a net loss of $1.612 million in Q3 2024 |
| Net loss for nine months ended September 30, 2025 | $1.003 million | Improved from a net loss of $2.974 million in the prior year period |
| Cash and cash equivalents as of September 30, 2025 | $1.120 million | Decreased significantly from $4.242 million at December 31, 2024 |
| Credit loss for nine months ended September 30, 2025 | $4.745 million | A new and substantial expense compared to zero in the prior year |
| Ownership for existing Arcadia stockholders post-Exchange Agreement | 10% | Significant dilution from the pending Roosevelt Resources LP transaction |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Arcadia Biosciences, Inc. (RKDA)?
Arcadia Biosciences, Inc. has 33 recent SEC filings from Jan 2024 to Apr 2026, including 18 8-K, 5 10-Q, 3 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RKDA filings?
Across 33 filings, the sentiment breakdown is: 2 bearish, 31 neutral. The dominant sentiment is neutral.
Where can I find Arcadia Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Arcadia Biosciences, Inc. (RKDA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Arcadia Biosciences, Inc.?
Key financial highlights from Arcadia Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RKDA?
The investment thesis for RKDA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Arcadia Biosciences, Inc.?
Key executives identified across Arcadia Biosciences, Inc.'s filings include Thomas J. Schaefer, Albert D. Bolles, Kevin Comcowich, Elliott Roosevelt, Jr., David A. Roosevelt and 6 others.
What are the main risk factors for Arcadia Biosciences, Inc. stock?
Of RKDA's 29 assessed filings, 2 were flagged high-risk, 14 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Arcadia Biosciences, Inc.?
Forward guidance and predictions for Arcadia Biosciences, Inc. are extracted from SEC filings as they are enriched.